The high concentration of Arg213 â†’ Gly extracellular superoxide dismutase (EC-SOD) in plasma is caused by a reduction of both heparin and collagen affinities by Petersen, Steen V. et al.
Biochem. J. (2005) 385, 427–432 (Printed in Great Britain) 427
The high concentration of Arg213→Gly extracellular superoxide
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The C-terminal region of EC-SOD (extracellular superoxide
dismutase) mediates the binding to both heparin/heparan sulphate
and type I collagen. A mutation (Arg213 → Gly; R213G) within
this extracellular matrix-binding region has recently been impli-
cated in the development of heart disease. This relatively common
mutation affects the heparin affinity, and the concentration of
EC-SOD in the plasma of R213G homozygous individuals is
increased 10- to 30-fold. In the present study we confirm, using
R213G EC-SOD purified from a homozygous individual, that the
heparin affinity is reduced. Significantly, the collagen affinity of
the R213G EC-SOD variant was similarly affected and both the
heparin and collagen affinities were reduced by 12-fold. Structural
analysis of synthetic extracellular matrix-binding regions suggests
that the mutation alters the secondary structure. We conclude that
the increased concentration of EC-SOD in the plasma of R213G
carriers is caused by a reduction in both heparin and collagen
affinities.
Key words: collagen, extracellular superoxide dismutase (EC-
SOD), oxidative damage, reduced affinity, Arg213 → Gly
(R213G), structure.
INTRODUCTION
Aerobic organisms have developed several defence mechanisms
to protect cellular components and tissues against oxidative
damage. Central to these defence mechanisms are the antioxidant
enzymes of which EC-SOD (extracellular superoxide dismutase
or SOD3) is an important component [1]. EC-SOD was initially
purified from human lung and is a 135 kDa homotetrameric
glycoprotein composed of two disulphide-linked dimers [2,3].
Recently, we have shown that the human EC-SOD subunit exists in
two folding variants with distinct disulphide bridge patterns; one
of the variants is enzymically active (aEC-SOD) and the other
one is inactive (iEC-SOD) [4].
The mature EC-SOD subunit (Trp1–Ala222) encompasses a
C-terminal ECM (extracellular matrix)-binding region (Arg210–
Ala222). This region binds heparin, other sulphated proteoglycans
[5–8] and collagen [9,10]. Immediately before secretion, the
EC-SOD subunit can be processed intracellularly to produce a
truncated variant lacking the ECM-binding region (Trp1–Glu209)
[11]. The process is a two-step proteolytic event involving an
initial cut by a member of the proprotein convertase family of
processing proteinases and a subsequent trimming by an unknown
carboxypeptidase [11–13]. Therefore native EC-SOD presents
variable affinity for heparin and collagen depending on the ratio
of intact and processed subunits in the tetramer: type A without
affinity (cleaved subunits only), type B with intermediate affinity
(composed of both intact and cleaved subunits) and type C with
high affinity (intact subunits only) [2,8,9]. The ECM-binding
region contains an unusually high content of charged amino acid
residues (seven Arg/Lys and two Glu) [14]. Six of the basic
amino acid residues are located in an Arg/Lys-cluster: Arg210-Lys-
Lys-Arg-Arg-Arg. Biophysical studies and secondary structure
predictions indicate that the ECM-binding region adopts an
α-helical structure [15]. This structure is probably important for
heparin binding [16]. However, a series of single amino acid
substitutions within the ECM-binding region of a recombinant
EC-SOD homologue suggested that the affinity for heparin is
minimally affected by structural perturbations of the ECM-
binding region and is more dependent on the charge density
[17]. Interestingly, a naturally occurring Arg213 → Gly (R213G)
mutation within the ECM-binding region exists [18–20]. The
concentration of EC-SOD in the plasma of homozygous
individuals is increased 10- to 30-fold and it has been suggested
that this phenotype is caused by a reduction of the heparin affinity
of the R213G variant [18,20–23].
In the present study, we show that the collagen affinity of R213G
EC-SOD is reduced and that the relative reduction in ECM affinity
is caused by a combination of reduced collagen and heparin
affinity. Structural analyses suggested that the perturbation of the
ECM-binding region imposed by Gly213 is responsible for the re-
duced affinity for collagen. This is in contrast with the heparin
affinity that depends more on the density of positively charged
amino acid residues [17]. We conclude that the increased
concentration of EC-SOD in the plasma of R213G carriers may
be explained not only by a reduced heparin affinity but also by
the disruption of the EC-SOD–collagen interaction. This may
increase the risk of oxidative damage to type I collagen of R213G
carriers and possibly affect the integrity of the vascular wall.
Abbreviations used: ECM, extracellular matrix; EC-SOD, EC superoxide dismutase; HRP, horseradish peroxidase; TFA, trifluoroacetic acid; TFE,
trifluoroethanol; R213G (etc.), Arg213 →Gly (etc.).
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MATERIALS AND METHODS
Proteins
Wild-type human EC-SOD was purified from human aorta as
described previously, except that the cation exchange chroma-
tography step was omitted [3]. The R213G variant of EC-SOD
was purified from plasma obtained from a homozygous R213G
individual using heparin- and immunoaffinity chromatography
as described previously [13]. BSA conjugated with heparin
(heparin–BSA) and HRP (horseradish peroxidase)-conjugated
goat anti-rabbit Ig were purchased from Sigma. HRP-conju-
gated rabbit anti-mouse IgG was obtained from Dako (Glostrup,
Denmark). A monoclonal antibody developed against native EC-
SOD used for ELISA was a gift from Dr R. P. Bowler (National
Jewish Medical and Research Center, Denver, CO, U.S.A.).
PAGE and Western blotting
Proteins were separated by SDS/PAGE in 5–15% polyacrylamide
gels [24]. Before electrophoresis, samples were boiled for 5 min in
the presence of 30 mM dithiothreitol and 1% SDS. For Western
blotting, proteins were electrophoretically transferred on to a
PVDF membrane in 10 mM 3-(cyclohexylamino)-1-propane
sulphonic acid/10%methanol (pH 11) [25]. The membranes were
blocked with 5% (w/v) skimmed milk in 20 mM Tris/HCl and
150 mM NaCl (pH 7.4). EC-SOD was subsequently detected by
enhanced chemiluminescence (Amersham Biosciences) using a
rabbit anti-human EC-SOD antiserum and HRP-conjugated goat
anti-rabbit Ig.
Analyses of the relative heparin affinities of wild-type
and R213G EC-SOD
Heparin–Sepharose chromatography
Heparin affinities were initially analysed by affinity chromato-
graphy using a 1 ml heparin–Sepharose column (HiTrap;
Amersham Biosciences) connected to an FPLC system. Human
plasma from a wild-type individual (25 ml) and from a homo-
zygous R213G individual (5 ml) was diluted 5-fold in 20 mM
Tris/HCl (pH 7.4) containing 5 mM EDTA (buffer A) and applied
to the column. The column was washed in buffer A and bound
proteins were subsequently eluted using a 1 ml/min flow rate and
a linear gradient (1%/min) from buffer A to buffer A containing
1 M NaCl. Fractions of 1 ml were collected and aliquots were
analysed by ELISA using heparin–BSA-coated microtitre plates
(see below) and by SDS/PAGE followed by Western blotting using
a polyclonal rabbit anti-EC-SOD antiserum. For these analyses,
we used 40 µl from the R213G fractions and 600 µl from the wild-
type fractions. The 600 µl aliquots were precipitated by using
trichloroacetic acid before SDS/PAGE analysis.
Heparin-ELISA
To assess further the heparin binding properties of wild-type and
R213G EC-SOD, we used an ELISA assay. Maxisorb microtitre
wells (Nunc, Roskilde, Denmark) were coated with 0.1 µg of
heparin–BSA in 100 µl of 50 mM NaHCO3 (pH 9.6) overnight
at 23 ◦C. The wells were emptied and residual binding sites were
blocked by the addition of 200 µl of 0.1% (w/v) BSA in 20 mM
Tris/HCl and 135 mM NaCl, pH 7.4 (TBS) for 1 h at 23 ◦C.
Two-fold dilution series of wild-type and R213G EC-SOD were
made with concentration ranging from 2560 to 2.5 ng/ml in TBS
containing 0.05% (v/v) Tween 20 (TBS-T). The dilutions were
assayed for SOD activity to verify that comparable concentrations
were used. Wells were incubated with 100 µl of the samples in
doublet for 90 min at 23 ◦C. After washing the wells three times
in TBS-T, 0.1 µg of monoclonal anti-EC-SOD antibody in 100 µl
of TBS-T was added and allowed to bind for 90 min at 23 ◦C.
Wells were washed in TBS-T and the bound primary antibody
was subsequently detected by the addition of HRP-conjugated
rabbit anti-mouse IgG antibody. Wells were developed using
the o-phenylenediamine dihydrochloride-system according to the
manufacturer’s instructions. Colour development was assessed by
absorption at 450 nm. The relative binding capacities of the wild-
type and R213G EC-SOD were estimated in the linear area with
an approximately parallel increase in absorbance. The influence
of ionic strength on heparin binding was also investigated by using
heparin–BSA-coated microtitre wells. Wild-type and R213G EC-
SOD were diluted to 100 ng/ml in 20 mM Tris/HCl containing 50–
500 mM NaCl. To the heparin–BSA-coated wells, 100 µl of the
samples in doublet were added and EC-SOD was allowed to bind
for 90 min at 23 ◦C. Bound EC-SOD was detected as described
above, except that 20 mM Tris/HCl and 50 mM NaCl (pH 7.4)
containing 0.05% Tween 20 were used for both the washing
steps and for dilution of primary and secondary antibodies.
ELISA analysis of the relative collagen affinities of wild-type
and R213G EC-SOD
The binding of EC-SOD to immobilized type I collagen was per-
formed essentially as described previously [9]. Briefly, maxisorb
microtitre wells (Nunc) were coated with 1 µg of collagen in
100 µl of 30 mM NaH2PO4/30 mM Tes/135 mM NaCl (pH 7.4)
overnight at 23 ◦C. The wells were emptied and blocked by
the addition of 20 mM NaH2PO4/50 mM NaCl/0.05% Tween
20, pH 7.4 (blocking buffer) for 1 h at 23 ◦C. Wild-type and
R213G EC-SOD were diluted in blocking buffer at the indicated
concentrations. Doublet samples (100 µl) were added to the wells
and EC-SOD was allowed to bind for 90 min at 23 ◦C. Bound EC-
SOD was detected as described in the analyses of the relative
heparin affinities of wild-type and R213G EC-SOD subsection
using 20 mM NaH2PO4/50 mM NaCl/0.05% Tween 20 (pH 7.4)
for all dilutions and washings.
Production of synthetic ECM-binding regions
To facilitate structural analyses of the ECM-binding region and
assess supposed differences between the wild-type and R213G
EC-SOD, we produced synthetic ECM-binding regions. Synthetic
peptides (residues Glu201-Ala222) representing the ECM-binding
regions of wild-type and R213G EC-SOD were assembled
in a 433A peptide synthesizer (Applied Biosystems, Foster
city, CA, U.S.A.) using Fmoc [N-(9-fluorenyl)methoxycarbonyl]
chemistry (FastMocTM; Applied Biosystems). The wild-type and
R213G peptides were N-ERQAREHSERKKRRRESECKAA-C
and N-ERQAREHSERKKGRRESECKAA-C respectively. The
peptides were synthesized using Fmoc-Ala resin as solid support,
de-blocked on ice for 3 h in 88% TFA (trifluoroacetic acid),
2% tri-isopropylsilane, 5% dithiothreitol, 5% water, extracted
using diethyl ether and recovered by centrifugation. The peptides
were then rehydrated in 10 mM NH4HCO3, desalted into 10 mM
NH4HCO3 using Sephadex G-10, and purified by reversed-
phase HPLC (Nova-Pak C18, 150 mm × 3.9 mm; Waters, Milford,
MA, U.S.A.). Peptides were applied in solvent A (0.1%
TFA), eluted by a linear gradient of 2%/min of solvent B
(90% acetonitrile containing 0.08% TFA) and detected by
absorption at 220 nm. Fractions were collected manually and
the structures of the peptides were verified by matrix-assisted-
laser desorption ionization mass spectrometry in a quadrupole–
time-of-flight Ultima Global mass spectrometer (Micromass,
Wythenshaw, Manchester, U.K.) as described previously [4]. The
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collected fractions were aliquoted and freeze-dried. To generate
homodimers, Cys219 was oxidized by atmospheric oxygen in
10 mM NaH2PO4 (pH 8.0). The peptide solutions were continu-
ously stirred for up to 5 days at 5 ◦C until more than 50% of the
peptide consisted of dimers. The progression of disulphide bridge
formation was monitored by reversed-phase HPLC analysis
using a C18 column (2.1 mm × 210 mm; Vydac, Hesperia, CA,
U.S.A.). Homodimers were subsequently purified by reversed-
phase HPLC using a C18 column (Nova-Pak) as described above.
Collected fractions were aliquoted, freeze-dried and stored at
−20 ◦C until further use. All chromatographic separations were
performed at 23 ◦C. The concentration of peptides was determined
by amino acid composition analysis [26].
Structural analysis by CD
Far-UV CD spectra of the synthetic peptides (wild-type and
R213G homodimers) were recorded at 20 ◦C in a closed 0.5 mm
Suprasil quartz cell (Helma) using the UV1 photo-biology
beamline with synchroton radiation provided by the ASTRID
storage ring (Institute for Storage Ring Facilities, University
of Aarhus; www.isa.au.dk). The peptides were dissolved at
0.2 mg/ml in 3 mM NaPO4 (pH 7.4) containing 0–40% (v/v) TFE
(trifluoroethanol). Three consecutive scans with 1 nm intervals
between 185 and 270 nm were collected and corrected for
background signal by subtracting the average of three scans of
solvent only. The CD spectra were normalized to give mean
residue ellipticity.
RESULTS
R213G EC-SOD elutes earlier from heparin–Sepharose
than wild-type EC-SOD
Plasma from wild-type (25 ml) or homozygous R213G (5 ml)
donors was subjected to heparin–Sepharose affinity chromato-
graphy to evaluate the relative heparin affinity of EC-SOD. EC-
SOD from wild-type individuals eluted from approx. 320 to
500 mM NaCl, as detected by ELISA (Figure 1A). EC-SOD
from a homozygous R213G individual eluted in a slightly broader
peak between 200 and 470 mM NaCl (Figure 1A). This indicates
that the heparin affinity of the R213G variant is reduced relative
to wild-type EC-SOD. In addition, the increased concentration
of EC-SOD in plasma of homozygous R213G individuals was
evident from this analysis according to the relative absorbance
(Figure 1A). Both the intact and cleaved subunits of wild-type EC-
SOD were detected by Western blotting (Figure 1B). Similarly,
the intact and the intermediate subunits of R213G EC-SOD were
detected (Figure 1B). The latter subunit is only partially processed,
producing a mature C-terminus at Gly213 and not at Glu209, the
mature C-terminus of the cleaved wild-type subunit [13].
The ratio between the intact and processed subunits in plasma-
derived EC-SOD from wild-type and R213G homozygous indi-
viduals was not significantly different, as estimated by Western
blotting (Figure 1B). The difference in heparin affinity observed
is therefore not likely to reside in a different distribution of intact
and processed subunits.
The binding of R213G EC-SOD to heparin is reduced
under physiological conditions
The influence of ionic strength on the heparin–EC-SOD inter-
action was analysed by using heparin–BSA-coated ELISA
plates. Samples were applied in a buffer containing increasing
concentrations of NaCl and the level of binding was evaluated
relative to the binding in the presence of 50 mM NaCl (Figure 2A).
Figure 1 Affinity purification of EC-SOD
(A) Plasma from a wild-type individual (25 ml) and a homozygous R213G individual (5 ml)
was applied to a heparin–Sepharose column and bound proteins were subsequently eluted
with NaCl (indicated by broken line). Collected fractions were analysed for the presence of
EC-SOD by using a heparin-based ELISA assay. The amount of EC-SOD is given as the absolute
absorbance. (B) Collected fractions were analysed by SDS/PAGE using 600 and 40 µl of
fractions representing wild-type and R213G plasma respectively. EC-SOD was subsequently
detected by using Western blotting. The intact, intermediate and cleaved forms of EC-SOD are
indicated. C, wild-type EC-SOD purified from human aorta used as control.
The binding of both wild-type and R213G EC-SOD was affected
by increasing the ionic strength. The absorbance produced by
wild-type and R213G EC-SOD was reduced by 50% in the
presence of 230 and 130 mM NaCl respectively (Figure 2A). At
physiological ionic strength, corresponding to approx. 137 mM
NaCl, no significant change was observed for the binding of
wild-type EC-SOD. However, the absorbance obtained from
R213G EC-SOD was reduced significantly at 137 mM NaCl
(Figure 2A). This suggests that the binding of R213G EC-
SOD to heparin is impaired under physiological conditions as
opposed to the wild-type protein. Both wild-type and R213G EC-
SOD bound in a dose-dependent manner at physiological ionic
strength, suggesting the presence of a saturable binding process
(Figure 2B). The binding curves were used to evaluate the relative
affinities of wild-type and R213G EC-SOD. The concentration of
R213G EC-SOD required to obtain the same level of bound wild-
type EC-SOD (based on the absorbance) was approx. 12-fold
higher in the parallel segment of the curves. Taken together,
these results show that the heparin affinity of R213G EC-SOD
is reduced approx. 12-fold when compared with the wild-type
EC-SOD.
The collagen-binding capacity of R213G EC-SOD
is significantly reduced
We have recently shown that the wild-type human and mouse
EC-SOD binds to type I collagen [9,10] and that this binding
is mediated by the ECM-binding region [9]. To evaluate the
effect of the R213G mutation, we examined the binding of
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Figure 2 Heparin-binding analysis of EC-SOD
(A) Approximately 100 ng/ml of wild-type and R213G EC-SOD were allowed to bind a
heparin–BSA-coated surface in the presence of increasing concentrations of NaCl. For
comparison, the binding of EC-SOD is depicted as the absorbance relative to the binding
in the presence of 50 mM NaCl. (B) Wild-type and R213G EC-SOD were diluted to the indicated
concentrations in a buffer containing 135 mM NaCl. The qualitative amount of bound material
is given as absorbance at 450 nm. The experiment was repeated three times producing similar
results. The data points represent the mean for doublet estimations and error bars indicate S.D.
Figure 3 Collagen-binding capacity of native EC-SOD
Microtitre wells were coated with type I collagen and subsequently incubated with wild-type
and R213G EC-SOD at the concentrations indicated. The R213G variant was purified from a
homozygous individual. The amount of bound material is given as absorbance at 450 nm. The
experiment was repeated three times producing similar results. The data points represent
the mean for doublet estimations and error bars indicate S.D.
purified wild-type and R213G EC-SOD to collagen-coated ELISA
plates. As previously shown, wild-type EC-SOD bound in a
dose-dependent manner suggesting a specific interaction [9]
(Figure 3). Significantly, the binding of R213G EC-SOD was
Figure 4 Structural analysis of homodimeric peptides
Far-UV CD spectra of (A) wild-type and (B) R213G homodimeric peptides were recorded at
20◦C. Peptides were analysed at 0.2 mg/ml in 3 mM NaPO4 (pH 7.4) in the presence of
increasing amounts of TFE, as indicated. Local peaks at 190, 208 and 222 nm indicate the pre-
sence of α-helical structures. The isodichroic point at 203 nm indicates a two-state process.
reduced (Figure 3). Approximately 12-fold more R213G EC-
SOD (2560 ng/ml) was required to produce the same response
as wild-type EC-SOD (200 ng/ml) in this assay. This differ-
ence indicates that the collagen affinity of R213G EC-SOD
relative to the wild-type protein is reduced by approximately
the same degree, as is the heparin affinity. This implies that the
amino acid residue at position 213 is essential for maintaining
the collagen binding capacity.
Gly213 disrupts the structure of the ECM-binding region
To study the structural impact of the R213G substitution, we ana-
lysed the synthetic homodimeric peptides representing the ECM-
binding region of both wild-type and R213G EC-SOD by
CD spectroscopy. Secondary structure predictions and experi-
mental evidence suggest that the ECM-binding region adopts an
α-helical structure in native EC-SOD [6,15]. The CD spectra
of both homodimers in a purely aqueous solution (0% TFE)
exhibited a singular negative peak at approx. 198 nm indicating
that they predominantly have random coil (unfolded) structures
(Figures 4A and 4B). To study the ability of the peptides to form
α-helical structures, we added increasing amounts of the organic
solvent TFE. TFE will induce the formation of an α-helix in
peptides that have the propensity to form this secondary structure
[27]. The CD spectra of the wild-type homodimer displayed an
increasing positive peak at 190 nm, and negative peaks at 208
and 222 nm (typical of α-helical structure) concomitant with
increasing TFE concentration (Figure 4A). This suggests that the
homodimer has the capacity to form an α-helix. The increase in
mean residue ellipticity at the wavelengths indicative of α-helix
formation was significantly reduced for the R213G homodimer
c© 2005 Biochemical Society
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(Figure 4B). The presence of an isodichroic point in both sets
of spectra indicates that the conversion from a predominantly
random coil into a predominantly α-helical structure is a two-
state process. These results show that the peptide variants have
a random-coiled structure in the absence of TFE. However,
in the presence of TFE the wild-type homodimer exhibited a
substantially higher propensity to form an α-helical structure
when compared with the R213G homodimer. Therefore it is
probable that the R213G mutation within the ECM-binding region
of native EC-SOD disrupts the α-helical structure.
DISCUSSION
The 10- to 30-fold increase in the EC-SOD concentration in the
plasma of R213G carriers has been suggested to reside in reduced
affinity for heparin and heparan sulphate [18,19,28]. We find, as
reported by others, that the heparin affinity of plasma-derived
R213G EC-SOD is lower than that of the wild-type form as
assessed by affinity chromatography [18,28,29]. The interactions
were further evaluated using purified components in an ELISA
assay. These analyses showed that the binding of R213G EC-
SOD was impaired at physiological ionic strength, whereas the
binding of wild-type EC-SOD was maintained (see Figure 2A).
This confirms that the ionic interaction between heparin and the
ECM-binding region of EC-SOD is perturbed by the R213G
substitution. Qualitative analysis of the heparin-binding capacity
of wild-type and R213G EC-SOD indicated that the heparin
affinity of R213G EC-SOD was reduced 12-fold relative to wild-
type EC-SOD (see Figure 2B). This difference in heparin affinity
is comparable with the 6-fold reduction determined by surface
plasmon resonance analysis using a recombinant protein variant
with the ECM-binding region [17].
The collagen binding capacity was also investigated by using
ELISA. A qualitative estimation indicated that the affinity of
R213G EC-SOD was reduced 12-fold relative to the wild-type
form. EC-SOD is found at high concentrations in systemic vessel
walls, especially the arteries where it is located throughout the
adventitia below the endothelium [30,31], but also in the arterial
intima surrounding the endothelial cells [32]. As the adventitia
contains high amounts of type I collagen, we speculated that EC-
SOD is bound to collagen in this area. Consequently, these areas
are probably less protected against oxidative stress in individuals
carrying the R213G EC-SOD variant. Significantly, a recent study
has shown that heterozygous R213G carriers have a higher risk
of ischaemic heart disease [23]. In human lung, EC-SOD was
found to be associated with type I collagen fibres and not diffusely
dispersed on cell surfaces [30]. The disruption of collagen binding
will probably reduce the antioxidant level in these areas. We have
recently illustrated the ability of EC-SOD to protect collagen
from oxidative fragmentation both in vitro and in vivo using a
mouse model of bleomycin-induced pulmonary fibrosis [9,10].
Therefore it is plausible that R213G carriers are more susceptible
to pulmonary diseases such as asthma, idiopathic pulmonary
fibrosis and chronic obstructive pulmonary disease where reactive
oxygen species are supposed to play an important role [33,34].
The R213G substitution probably destabilizes an α-helical
structure because Arg213, in contrast with Gly213, has the capacity
to interact with Glu209 [17]. Analysis by CD spectroscopy in
the presence of increasing amounts of TFE confirmed that the
wild-type dimer is more likely to form an α-helical structure
compared with the R213G dimer. Therefore it is probable that the
tertiary structure of the ECM-binding region of R213G EC-SOD is
altered when compared with wild-type EC-SOD. When Stenlund
et al. [17] analysed the heparin affinities of artificial EC-SOD
homologues encompassing single Arg/Lys → Ala substitutions
in the Arg/Lys-cluster they found that the affinity decreased by 2-
to 6-fold. In addition, they showed that a series of mutations
disrupting the α-helical structure of the ECM-binding region
(E206P, K212P and R215P) had similar effects on the heparin
affinity as the corresponding Ala variants. As discussed by these
authors, this indicates that the ECM-binding region has sufficient
flexibility to accept several disruptive amino acid substitutions and
sustain some heparin-binding activity. This hypothesis implies
that the heparin–heparan sulphate binding is less affected by
structural changes and more dependent on the charge density of
the ECM-binding region. The structural organization of the rod-
shaped collagen fibril will probably impose structural constraints
on the EC-SOD–collagen interaction. Owing to the size and
heterogeneity of complexes between collagen fibrils and collagen-
binding proteins, there is only limited structural information
available [35,36]. However, it is probable that a more rigid
molecule such as collagen will impose higher structural demands
on EC-SOD compared with a more flexible molecule like heparin.
The structural disruption imposed by the R213G substitution may
thus account for the reduced collagen-binding capacity.
We have shown that R213G EC-SOD has a significantly
reduced affinity for collagen in addition to a reduced heparin-
binding capacity. The relative contribution of the reduced affinities
to the increased concentration of EC-SOD in the plasma of
individuals carrying the R213G mutation is difficult to assess.
Nonetheless, the increased concentration of EC-SOD in plasma
of affected individuals may correspondingly reflect a reduced
antioxidant level in tissue and consequently a concomitant
increase in radical-mediated disease susceptibility. Indeed, it
has recently been shown that heterozygous individuals have an
increased risk of acquiring ischaemic heart disease [23]. Similarly,
a prospective study in a selected population of haemodialysis
patients showed that heterozygotes had an increased risk of death
from ischaemic heart disease and cerebrovasular disease [37]. In
addition, mice lacking EC-SOD develop normally; however, when
stressed by hyperoxia they display an increased mortality
when compared with wild-type animals [38]. It may thus be
hypothesized that an R213G phenotype will be observed primarily
in combination with a disease creating increased oxidative stress.
Our finding that the R213G mutation disrupts the interaction with
collagen may indicate that the affected individuals will be more
susceptible to diseases where collagenous tissue is destroyed.
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